Results 201 to 210 of about 380,673 (266)

Structural optimization of drug molecules with incrementally trained language models. [PDF]

Nat Commun
Hörmann T, Mayer D, Lewandowski M, Hunklinger A, Wein T, Merk D.   +5 more
europepmc   +1 more source

Reconstructing enzyme evolution by protein engineering

FEBS Letters, EarlyView.
Natural enzyme evolution can be retraced by protein engineering methods such as directed evolution, rational design, and ancestral sequence reconstruction. These approaches reveal how enzymes emerged from ligand‐binding scaffolds, developed varying substrate preferences, formed oligomeric complexes, adapted to environmental changes, and evolved novel ...
Lukas Drexler, Markus R. Busch, Reinhard Sterner   +2 more
wiley   +1 more source

<i>In vitro</i> assessment of foot-and-mouth disease vaccine immunogenicity: advances, challenges, and ethical considerations. [PDF]

Front Vet Sci
Othusitse L, Kabelo TI, Nkwe KA, Seoke L, Fana EM, Lebani K.   +5 more
europepmc   +1 more source

Discovery of 2H-Pyrrolo[3,4‑<i>c</i>]pyridin-3-one Derivatives as Type-III c‑MET Inhibitors Enabled by Free-Energy Perturbation Calculations. [PDF]

ACS Med Chem Lett
Therrien E, Feng S, Amberg-Johnson K, Shaikh N, Patil P, Majumdar S, Abraham N, Eiler D, Kutter S, Albanese SK, Haldar S, Kroeck KG, Atsriku C, Gerasyuto AI, Levinson AM.   +14 more
europepmc   +1 more source

Structural determinants of ligand response specificity in the mast cell activating GPCR, MRGPRX2. [PDF]

J Biol Chem
Adeosun AAR, Agosto MA, Lichtarge O, Wensel TG.   +3 more
europepmc   +1 more source

Normalizing Covalent Potency for Electrophilicity with Ligand Reactivity Efficiency. [PDF]

J Med Chem
Horning BD, Kingston C, Simon GM, Patricelli MP, Weinstein DS, Cook BN.   +5 more
europepmc   +1 more source

Discovery of Potent 1,3-Cyclobutane-Containing Dual A_2A/A_2B Receptor Antagonists with Low Projected Human Dose for the Treatment of Cancer. [PDF]

ACS Med Chem Lett
Brill ZG, Christian AH, Rico L, Schneider SE, Phillips EM, Winston MS, Krishnamurthy H, Hennessy ET, Mansoor UF, Xiao D, Su J, Liu P, Plummer C, Palmieri A, Vela Ramirez J, Hill A, Dewey W, Tatosian D, Rindgen D, Ogunbodede O, Smotrov N, Piesvaux J, Ciaccio P, Fan P, Afshar R, Daublain P, Presland J, Otte KM, Ali A, Cumming J, Ranganath S, DeMong D.   +31 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Potency and Prostatectomy

British Journal of Urology, 1977
A prospective questionnaire study with a 6-month follow-up was carried out to determine the incidence of post-prostatectomy impotence. 57% of patients were potent at the time of operation. A man with full potency had a 4% chance of becoming totally impotent and a 3% chance of becoming partially impotent. A man with failing preoperative potency had a 10%
T B, Hargreave, T P, Stephenson
openaire   +2 more sources